The enrichment of nuclear mTOR, AR and SMARCD1 in MDA PCa 2b has indicated a more aggressive tumor phenotype in AA PCa vs. EA PCa (i.e., LNCaP, an androgen-dependent EA PCa with much lower nuclear mTOR, AR, and SMARCD1). The gene discussed is SMARCD1; the disease is neoplasm.